Readoutin 164d
Xenon Pharmaceuticals Inc. — Azetukalner
Phase 3 primary completion: A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3).
- Date
- May 2027
- Type
- Readout
- Indication
- Major Depressive Disorder
Readoutin 164d
Phase 3 primary completion: A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.